Abstract:Background: Variation at TP63 has recently been shown to be associated with non-small cell lung cancer patients (NSCLC) in the Chinese population. There is some clinical evidence for the use of TP63 mutations as prognostic and predictive biomarker. The aim of this study is to investigate mutations and prognosis of NSCLC harboring TP63 mutations. Methods: A total of 1236 patients with non-small-cell lung cancer were recruited between July 2012 and December 2016. The status of TP63 mutations and other genes were detected by next generation sequencing. Results: TP63 gene mutation rate was 2.02% (25/1236) in non-small cell lung cancer, including R643* (1 patient), H247N (1 patient), A139V (1 patient), V626F (1 patient), Q70* (1 patient), Q274E (1 patient), H615D (1 patient), R350T (1 patient), Y202Kfs*29 (1 patient), P229H (1 patient), M40V (1 patient), E409Q (1 patient), V179M (1 patient), W658* (1 patient), S365* (1 patient), T193M (1 patient), L50F (1 patient), A554E (1 patient), R226H (1 patient), Q99* (1 patient), S310N (1 patient), T169N (1 patient), R266Q (1 patient), D372H (1 patient), and P492T (1 patient), and median overall survival (OS) for these patients was 15.0 months. Among them, all patients were TP63 gene with co-occurring mutations. Briefly, patients with (n = 5) or without (n = 20) co-occurring EGFR mutations had a median OS of 22.5 months and 14.0 months respectively (p = 0.23); patients with (n = 21) or without (n = 4) co-occurring TP53 mutations had a median OS of 15.0 months and 13.0 months respectively (p = 0.33); patients with (n = 5) or without (n = 20) co-occurring BRAF mutations had a median OS of 14.0 months and 15.0 months respectively (p = 0.72); patients with (n = 5) or without (n = 20) co-occurring KRAS mutations had a median OS of 6.0 months and not up to now respectively (P < 0.01). Conclusions: TP63 is structurally and functionally similar to TP53 and their activity as transcription factors is regulated by a wide repertoire of shared and unique post-translational modifications and interactions with regulatory cofactors. EGFR, TP53 and BRAF gene accompanied may have less correlation with TP63 mutation in NSCLC patients. KRAS accompanied mutations might play a worse prognosis in TP63 gene mutation NSCLC. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

Frequency and Features of TP53 Mutation in 30 Chinese Patients with Sporadic Basal Cell Carcinoma.

Unique Features of PTCH1 Mutation Spectrum in Chinese Sporadic Basal Cell Carcinoma

Mutations of PTEN Gene in 117 Chinese Patients with Malignant Melanoma and Their Clinical Significance

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

[Germline mutations of TP53 gene among Chinese families with high risk for breast cancer].

p53 inactivating mutations in chinese breast carcinomas.

Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer

Association of TP53 Codon 72 Polymorphism with Cervical Cancer Risk in Chinese Women

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA

Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study

Prevalence and Spectrum of AKT1, PIK3CA, PTEN and TP53 Somatic Mutations in Chinese Breast Cancer Patients

[Retrospective Analysis for Clinical and Histopathological Characteristics of Basal Cell Carcinoma in 418 Patients].

Clinicopathological and Prognostic Impact of Somatic Mutations in Chinese Patients with Clear Cell Renal Cell Carcinoma

Early-onset of sporadic basal-cell carcinoma: germline mutations in the TP53, PTCH, and XPD genes

Cmar_a_298729 3303..3316

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

Clinicopathologic Characteristics of Patients with TP63 Mutations in Chinese Non-Small Cell Lung Cancer

BRCA1 and BRCA2 mutations of 140 Chinese breast cancer patients with genetic high risk

Comprehensive Molecular Characterization of Chinese Patients with Intrahepatic and Extrahepatic Cholangiocarcinoma.

Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High BRAF Mutation Allele Frequency, Multiple Driver Gene Mutations, and RET Fusion May Indicate More Advanced TN Stage

Genetic landscape of papillary thyroid carcinoma in the Chinese population